Attovia Therapeutics Appoints Huber Chen, M.D., as Chief Medical Officer

Based in the Bay Area, Attovia Therapeutics is creating a pipeline of biotherapeutics with an initial focus on immune-mediated diseases. The company leverages Attobody™, a novel biologics platform, to generate small format biparatopic binders that offer stronger efficacy and a broader universe of druggable epitopes compared to traditional approaches.

Dr. Hubert Chen, accomplished drug developer and pharma executive, joins Attovia as Chief Medical Officer.  Dr. Chen brings extensive clinical and industry leadership experience in drug development and joins Attovia from Krystal Biotech (NASDAQ: KRYS), where he was Senior Vice President of Clinical Development. At Attovia, Dr. Chen will lead the company’s clinical development and regulatory functions and will serve on the Executive Committee.

At Krystal Biotech, Dr. Chen played an instrumental role in the approval of the first topical gene therapy, Vyjuvek®, for the treatment of dystrophic epidermolysis bullosa. Prior to Krystal, Dr. Chen was at Genentech/Roche where he held clinical leadership positions across both early and late-stage development. As the global development lead for Xolair®, he successfully led the sBLA filing for chronic spontaneous urticaria. During his tenure at Genentech, he also expanded the immunology portfolio by leading the entry of three novel molecules into first-in-human/proof-of-concept trials, including an anti-IL-13 bispecific, and the acquisition of two early-stage clinical assets, which subsequently advanced to later stage trials. Dr. Chen started his career as an Assistant Professor in the Division of Pulmonary and Critical Care at UCSF, where he served as a clinical faculty member for over a decade. He received a medical degree from Stanford and a master of public health degree from Harvard. He completed his post-doctoral residency/fellowship training at Stanford and UCSF. He is board-certified in Internal Medicine, Pulmonary Medicine, and Critical Care Medicine.